ArticleThe lancet. Diabetes & endocrinology2019

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.

Hakim-Moulay Dehbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.